Difference between revisions of "Volasertib (BI-6727)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
||
| Line 9: | Line 9: | ||
*4/14/2014: Granted FDA orphan drug status for treatment of [[Acute myeloid leukemia | acute myeloid leukemia]]. | *4/14/2014: Granted FDA orphan drug status for treatment of [[Acute myeloid leukemia | acute myeloid leukemia]]. | ||
| − | [[Category: | + | [[Category:Drugs]] |
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
Revision as of 22:53, 13 June 2018
Mechanism of action
Polo-like kinase 1 (PLK1) inhibitor
Preliminary data
Acute myeloid leukemia
- Döhner H, Lübbert M, Fiedler W, Fouillard L, Haaland A, Brandwein JM, Lepretre S, Reman O, Turlure P, Ottmann OG, Müller-Tidow C, Krämer A, Raffoux E, Döhner K, Schlenk RF, Voss F, Taube T, Fritsch H, Maertens J. Randomized, phase 2 trial comparing low-dose cytarabine with or without volasertib in AML patients not suitable for intensive induction therapy. Blood. 2014 Aug 28;124(9):1426-33. Epub 2014 Jul 8. link to original article link to PMC article PubMed
History of changes in FDA indication
- 4/14/2014: Granted FDA orphan drug status for treatment of acute myeloid leukemia.